FDA Scrutiny on Sarepta - Search News

Order byBest matchMost fresh

FDA, Sarepta Therapeutics and gene

· 7h · on MSN

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Shares of drugmaker Sarepta Therapeutics continued to sink Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of its gene therapy following s...

Continue reading

· 3d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

BioSpace · 10h

Sarepta Concedes to FDA Request, Suspends US Shipments of Elevidys

Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.

Sarepta Therapeutics was falling again in premarket trading Tuesday as its future looks increasingly shaky after it agreed to halt shipments of its Elevidys drug under pressure from the Food and Drug ...

Continue reading

In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

Pharmalittle: We’re reading about Sarepta resisting FDA over Elevidys, agency naming top drug regulator, and more

10h

Sarepta Therapeutics cuts Durham jobs amid mass layoffs, FDA scrutiny

A Massachusetts biotechnology company is laying off 21 employees in Durham amid a broader restructuring and pressure from federal regulators.

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.